🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

What if you isolated an influenza A virus that didn’t look like the 18 subtypes you’ve seen before? A Taylor & Francis Research Insights study did just that: bit.ly/3DNNvB4 The diversity & continuous evolution of flu viruses calls for intervention strategies that confer broad protection.

US #fluvaccine season is underway, & new CDC data show why vaccines are a crucial piece of #influenza protection. We’re developing preventative treatments that could be layered on top of #flu vaccines to give additional protection. More: bit.ly/3EBYjTi

Our Board member, David David Schenkein, highlighted Leyden Labs as a select investment on the list of The Insider’s top VCs in Boston. We’re proud to partner w David & the GV to develop better ways to protect the world from #respiratoryviruses. bit.ly/3rQCzQP

Have you heard of Disease X? Coined by the World Health Organization (WHO), Disease X is a placeholder name for the next virus that could set off a pandemic. Bloomberg examines how scientists are preparing for a viral threat whose identity is still unknown: bloom.bg/3EZvpMT

Senior Scientist María Ángeles Corral is part of our CMC team. Her #proteinscience expertise informs our work to create antibodies that can harness mucosal immunity & provide broad protection — with the goal of freeing you from the threat of #respiratoryviruses.

#DYK the Dutch city of Leiden, where Leyden Labs is based, has connections to U.S. Thanksgiving? Some of the Pilgrims spent time in Leiden before traveling to America, & the holiday is celebrated in Leiden today. More from Smithsonian Magazine archives: bit.ly/46fi7am

We’re using new technologies to optimize the administration of antibodies via nasal spray. Take a glimpse into our Leiden #laboratory where we’re developing intranasal products to protect against respiratory viruses. Learn more: leydenlabs.com

#DYK it’s National Influenza Vaccination Week? If you haven’t already, it’s a great time to get your #FluVax. At Leyden Labs we’re working hard to #FightFlu by developing novel products that could provide broad protection against existing and new strains of #flu.  #NIVW

Your body’s first line of defense against an airborne virus is #mucosal_immunity–the immune attack mounted by the cells lining the nose & throat. Our nasal sprays will deliver antibodies directly to the nasal mucosa that aim to provide the user w/ immediate anti-viral protection.

We’re pleased to have been invited to speak at #JPM24, where our CEO Koenraad Wiedhaup will present the latest on our mucosal programs and platform. Hope to see you there! #biotechnology #mucosal_immunity

Happy holidays to all our Leyden Labs community. Our mission is to enable people to live life to the fullest; during this holiday season, may you fully enjoy time spent with those dear to you.

New research has found that, like Covid, #flu can cause ‘long haul’ symptoms for months after infection – another reason that flu prevention is critical. We’re working to develop novel preventatives for flu & other viruses. More from The Guardian: bit.ly/3RUibIQ

On Wednesday CEO Koenraad Wiedhaup will be presenting at #JPM24, where he’ll be sharing our progress in preventing respiratory viral infections by leveraging #mucosal_immunity. Details here: bit.ly/3NWekIN #flu #biotechnology

Our CEO Koenraad Wiedhaup took the stage at #JPM24 this week to talk about #mucosal_immunity and Leyden Labs’ progress toward addressing an important gap in protection against #flu, coronaviruses, & other respiratory viruses.

We’re obsessed with the nose: our 1st line of defense against pathogens like #flu & coronaviruses. By deeply understanding the nasal mucosa, we aim to develop products to bolster our immunity right where the battle against respiratory viruses begins: in the nose. #nasal_obesssion

#Influenza is a familiar threat but it's still dangerous: Since Oct, CDC reports 230,000 #flu hospitalizations, & there are months of flu season left. We're developing products to better protect people against #flu & other viruses. Explore the data: bit.ly/428xQrn

Exciting news: Our latest research shows influenza antibody CR9114 protects intranasally against #avianflu incl. #H5N1 in vivo. Continued spread of H5N1 among animals has increased the importance of pandemic preparedness. Read our paper in Scientific Reports: bit.ly/48laZdF

Our #nasal_obsession is all about attacking respiratory viruses where they attack us: in the nose. Our platform allows for anchoring antibodies in the mucosa to help prevent infection and illness. More: leydenlabs.com/#approach

Justin Crawford is an accomplished biochemist who oversees our Mucosal Platform Discovery team. This multidisciplinary group is leading our efforts to cement Leyden Labs as masters of #mucosal_immunity. Learn more about our team: leydenlabs.com

Meet Ana Ward, a Business Development Manager here at Leyden Labs. She sources and evaluates external assets and technologies that have the potential to advance our work to free people from the threat of respiratory #viruses. Learn more about our team: leydenlabs.com